An Open-Label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate

Trial Profile

An Open-Label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Motesanib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 24 Apr 2014 Last checked against ClinicalTrials.gov record.
    • 26 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 02 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top